National Biomedical Research Act This bill establishes and makes deposits through FY2029 into the Biomedical Innovation Fund for initiatives at the National Institutes of Health and the Food and Drug Administration for advancing medical innovation, including by supporting (1) research for disease prevention, diagnosis, and treatment; (2) research for diseases that disproportionally account for federal health care spending; (3) the development, review, and post-market surveillance of medical products; and (4) other innovative research.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Administrative law and regulatory proceduresAgingAppropriationsBudget deficits and national debtCancerChild healthComputers and information technologyDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyEducation programs fundingEnvironmental healthExecutive agency funding and structureFood and Drug Administration (FDA)GeneticsGovernment trust fundsHealth care costs and insuranceHealth information and medical recordsHealth personnelHealth programs administration and fundingHealth promotion and preventive careHealth technology, devices, suppliesImmunology and vaccinationMedicaidMedical educationMedical researchMedical tests and diagnostic methodsMedicareMilitary medicineMinority healthNational Institutes of Health (NIH)Neurological disordersNutrition and dietPhysical fitness and lifestylePoverty and welfare assistanceResearch administration and funding
National Biomedical Research Act
USA116th CongressS-3161| Senate
| Updated: 1/8/2020
National Biomedical Research Act This bill establishes and makes deposits through FY2029 into the Biomedical Innovation Fund for initiatives at the National Institutes of Health and the Food and Drug Administration for advancing medical innovation, including by supporting (1) research for disease prevention, diagnosis, and treatment; (2) research for diseases that disproportionally account for federal health care spending; (3) the development, review, and post-market surveillance of medical products; and (4) other innovative research.
Administrative law and regulatory proceduresAgingAppropriationsBudget deficits and national debtCancerChild healthComputers and information technologyDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyEducation programs fundingEnvironmental healthExecutive agency funding and structureFood and Drug Administration (FDA)GeneticsGovernment trust fundsHealth care costs and insuranceHealth information and medical recordsHealth personnelHealth programs administration and fundingHealth promotion and preventive careHealth technology, devices, suppliesImmunology and vaccinationMedicaidMedical educationMedical researchMedical tests and diagnostic methodsMedicareMilitary medicineMinority healthNational Institutes of Health (NIH)Neurological disordersNutrition and dietPhysical fitness and lifestylePoverty and welfare assistanceResearch administration and funding